Guwahati Mail

“Cognitive Impairment Associated with Schizophrenia Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cognitive Impairment Associated with Schizophrenia Market.

The Cognitive Impairment Associated with Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cognitive Impairment Associated with Schizophrenia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cognitive Impairment Associated with Schizophrenia treatment therapies with a considerable amount of success over the years.

• Cognitive Impairment Associated with Schizophrenia companies working in the treatment market are Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others, are developing therapies for the Cognitive Impairment Associated with Schizophrenia treatment

• Emerging Cognitive Impairment Associated with Schizophrenia therapies in the different phases of clinical trials are- Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others are expected to have a significant impact on the Cognitive Impairment Associated with Schizophrenia market in the coming years.

• In January 2025, Boehringer Ingelheim reported top-line results from its Phase III CONNEX clinical program assessing iclepertin for cognitive impairment in adults with schizophrenia. The study did not meet its primary or key secondary endpoints. After six months, no statistically significant improvements in cognition or functioning were observed in patients receiving iclepertin compared to placebo. However, across all three trials, iclepertin—a glycine transporter 1 (GlyT1) inhibitor—was generally well tolerated, and its safety profile remained consistent with earlier research.

• In December 2024, Kynexis, a biotech company specializing in precision treatments for brain disorders, has announced encouraging topline results from its first-in-human Phase 1 clinical trial. The study, conducted in healthy volunteers, assessed the safety, tolerability, and pharmacokinetics of KYN-5356—an innovative, first-in-class oral small molecule KAT-II inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS). The trial included both single and multiple ascending dose evaluations. In addition, the multiple ascending dose phase explored central pharmacodynamic biomarkers and cognitive performance to confirm target engagement.

• In Sepetmber 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that its Phase 2 ERUDITE™ clinical trial evaluating the investigational drug luvadaxistat (NBI-1065844) did not achieve its primary goal of improving cognitive impairment in individuals with schizophrenia. This was the second Phase 2 trial for luvadaxistat, following the earlier INTERACT™ study. However, the ERUDITE trial failed to reproduce the positive cognitive outcomes previously observed, potentially due to significant variability in cognitive assessments among participants and possible imbalances in baseline characteristics across treatment groups

• In April 2024, Alto Neuroscience has announced positive outcomes from its Phase I clinical trial of the PDE4 inhibitor ALTO-101 for treating cognitive impairment associated with schizophrenia (CIAS). The study showed that ALTO-101, delivered via a transdermal delivery system (TDS), had better tolerability and improved pharmacokinetics compared to oral administration. The Phase I trial aimed to evaluate the safety, tolerability, pharmacokinetics, and adhesion properties of the transdermal formulation of ALTO-101, in contrast to its oral form, in healthy volunteers.

Cognitive Impairment Associated with Schizophrenia Overview

Cognitive impairment associated with schizophrenia (CIAS) refers to the deficits in various cognitive functions experienced by individuals with schizophrenia. These cognitive deficits are a core feature of the disorder and can significantly impact daily functioning, social interactions, and overall quality of life.

Get a Free Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight

Emerging Cognitive Impairment Associated with Schizophrenia Drugs Under Different Phases of Clinical Development Include:

• Research programme: Autifony Therapeutics

• CY6463: Cyclerion Therapeutics

• BIIB104: Biogen

• Luvadaxistat: Neurocrine Biosciences

• RL-007: Recognify Life Sciences

• Iclepertin: Boehringer Ingelheim

• MEM 3454: Memory Pharmaceuticals

• Eltoprazine: Amarantus BioScience

• Luvadaxistat: Neurocrine Biosciences

• Basmisanil: Hoffmann-La Roche

• LY500307: Eli Lilly and Company

• armodafinil: Cephalon

• Extended-release galantamine hydrobromide: Johnson & Johnson Pharma

• Luvadaxistat: Takeda

Cognitive Impairment Associated with Schizophrenia Route of Administration

Cognitive Impairment Associated with Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Cognitive Impairment Associated with Schizophrenia Molecule Type

Cognitive Impairment Associated with Schizophrenia Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics Assessment

• Cognitive Impairment Associated with Schizophrenia Assessment by Product Type

• Cognitive Impairment Associated with Schizophrenia By Stage and Product Type

• Cognitive Impairment Associated with Schizophrenia Assessment by Route of Administration

• Cognitive Impairment Associated with Schizophrenia By Stage and Route of Administration

• Cognitive Impairment Associated with Schizophrenia Assessment by Molecule Type

• Cognitive Impairment Associated with Schizophrenia by Stage and Molecule Type

DelveInsight’s Cognitive Impairment Associated with Schizophrenia Report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cognitive Impairment Associated with Schizophrenia product details are provided in the report. Download the Cognitive Impairment Associated with Schizophrenia pipeline report to learn more about the emerging Cognitive Impairment Associated with Schizophrenia therapies

Some of the key companies in the Cognitive Impairment Associated with Schizophrenia Therapeutics Market include:

Key companies developing therapies for Cognitive Impairment Associated with Schizophrenia are – Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Atai Life Sciences NV, and others.

Cognitive Impairment Associated with Schizophrenia Pipeline Analysis:

The Cognitive Impairment Associated with Schizophrenia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cognitive Impairment Associated with Schizophrenia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cognitive Impairment Associated with Schizophrenia Treatment.

• Cognitive Impairment Associated with Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cognitive Impairment Associated with Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cognitive Impairment Associated with Schizophrenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia drugs and therapies

Cognitive Impairment Associated with Schizophrenia Pipeline Market Drivers

• Increase in Prevalence of Mental Disturbances, rise in Awareness About Mental Health are some of the important factors that are fueling the Cognitive Impairment Associated with Schizophrenia Market.

Cognitive Impairment Associated with Schizophrenia Pipeline Market Barriers

• However, side-effects associated with the treatment of Cognitive Impairment Associated with Schizophrenia, stigma associated with mental illness and other factors are creating obstacles in the Cognitive Impairment Associated with Schizophrenia Market growth.

Scope of Cognitive Impairment Associated with Schizophrenia Pipeline Drug Insight

• Coverage: Global

• Key Cognitive Impairment Associated with Schizophrenia Companies: Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others

• Key Cognitive Impairment Associated with Schizophrenia Therapies: Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others

• Cognitive Impairment Associated with Schizophrenia Therapeutic Assessment: Cognitive Impairment Associated with Schizophrenia current marketed and Cognitive Impairment Associated with Schizophrenia emerging therapies

• Cognitive Impairment Associated with Schizophrenia Market Dynamics: Cognitive Impairment Associated with Schizophrenia market drivers and Cognitive Impairment Associated with Schizophrenia market barriers

Request for Sample PDF Report for Cognitive Impairment Associated with Schizophrenia Pipeline Assessment and clinical trials

Table of Contents

1. Cognitive Impairment Associated with Schizophrenia Report Introduction

2. Cognitive Impairment Associated with Schizophrenia Executive Summary

3. Cognitive Impairment Associated with Schizophrenia Overview

4. Cognitive Impairment Associated with Schizophrenia- Analytical Perspective In-depth Commercial Assessment

5. Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics

6. Cognitive Impairment Associated with Schizophrenia Late Stage Products (Phase II/III)

7. Cognitive Impairment Associated with Schizophrenia Mid Stage Products (Phase II)

8. Cognitive Impairment Associated with Schizophrenia Early Stage Products (Phase I)

9. Cognitive Impairment Associated with Schizophrenia Preclinical Stage Products

10. Cognitive Impairment Associated with Schizophrenia Therapeutics Assessment

11. Cognitive Impairment Associated with Schizophrenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cognitive Impairment Associated with Schizophrenia Key Companies

14. Cognitive Impairment Associated with Schizophrenia Key Products

15. Cognitive Impairment Associated with Schizophrenia Unmet Needs

16 . Cognitive Impairment Associated with Schizophrenia Market Drivers and Barriers

17. Cognitive Impairment Associated with Schizophrenia Future Perspectives and Conclusion

18. Cognitive Impairment Associated with Schizophrenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/